- Home
- SENEA vs CRMD Comparison
SENEA vs CRMD Comparison
Compare SENEA & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEA
- CRMD
- Stock Information
- Founded
- SENEA 1949
- CRMD 2006
- Country
- SENEA United States
- CRMD United States
- Employees
- SENEA N/A
- CRMD N/A
- Industry
- SENEA Packaged Foods
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- SENEA Consumer Staples
- CRMD Health Care
- Exchange
- SENEA Nasdaq
- CRMD Nasdaq
- Market Cap
- SENEA 557.7M
- CRMD 645.0M
- IPO Year
- SENEA N/A
- CRMD 2010
- Fundamental
- Price
- SENEA $80.49
- CRMD $10.13
- Analyst Decision
- SENEA
- CRMD Strong Buy
- Analyst Count
- SENEA 0
- CRMD 6
- Target Price
- SENEA N/A
- CRMD $15.67
- AVG Volume (30 Days)
- SENEA 13.7K
- CRMD 906.0K
- Earning Date
- SENEA 02-06-2025
- CRMD 03-11-2025
- Dividend Yield
- SENEA N/A
- CRMD N/A
- EPS Growth
- SENEA 25.61
- CRMD N/A
- EPS
- SENEA 5.45
- CRMD N/A
- Revenue
- SENEA $1,541,031,000.00
- CRMD $12,262,234.00
- Revenue This Year
- SENEA N/A
- CRMD N/A
- Revenue Next Year
- SENEA N/A
- CRMD $234.92
- P/E Ratio
- SENEA $14.77
- CRMD N/A
- Revenue Growth
- SENEA 4.01
- CRMD 41184.20
- 52 Week Low
- SENEA $46.56
- CRMD $3.03
- 52 Week High
- SENEA $81.45
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- SENEA 65.40
- CRMD 44.90
- Support Level
- SENEA $77.08
- CRMD $9.79
- Resistance Level
- SENEA $81.45
- CRMD $11.28
- Average True Range (ATR)
- SENEA 2.00
- CRMD 0.51
- MACD
- SENEA 0.54
- CRMD -0.05
- Stochastic Oscillator
- SENEA 90.83
- CRMD 23.84
About SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.